Orchard Therapeutics PLC (NASDAQ:ORTX)

0.4683
Delayed Data
As of May 16
 -0.0058 / -1.22%
Today’s Change
0.41
Today|||52-Week Range
5.69
-64.52%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$57.3M

Company Description

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

Contact Information

Orchard Therapeutics Plc
108 Cannon Street
London Greater London EC4N 6EU
P:442038088286
Investor Relations:
(862) 242-0764

Employees

Shareholders

Individual stakeholders9.08%
Other institutional23.83%
Mutual fund holders14.18%

Top Executives

Bobby GasparChief Executive Officer & Executive Director
Frank E. ThomasPresident, COO, CFO & Chief Accounting Officer
Nicoletta LoggiaChief Technical Officer
Fulvio MavilioChief Scientific Officer
Leslie MeltzerChief Medical Officer